Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
Overview
In8Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative gamma-delta T cell immunotherapies for cancer treatment. Utilizing state-of-the-art approaches such as allogeneic, autologous, and genetically modified T cells, the company is at the forefront of applying advanced immunology in the fight against both solid and hematologic malignancies. By leveraging its robust DeltEx platform, In8Bio is pioneering the integration of cell-based therapies into standard clinical protocols, a subject of high relevance in the fields of oncology and immunotherapy.
Clinical Programs and Technological Innovation
The company is deeply engaged in multiple clinical programs that advance its gamma-delta T cell product candidates into various stages of clinical investigation. Its innovative approach harnesses the unique ability of gamma-delta T cells to recognize and destroy cancer cells while differentiating between healthy and diseased tissues. The immunotherapies developed by In8Bio are designed to overcome current challenges in cancer treatment by demonstrating resilience in the presence of conventional modalities such as chemotherapy. This novel methodology indicates a significant step forward in addressing persistent gaps in progression-free survival for patients afflicted with difficult-to-treat cancers.
Pipeline and Portfolio
In8Bio maintains a diverse portfolio of cell therapy candidates that target both solid tumors, such as aggressive brain cancers, and liquid tumors, including high-risk hematologic malignancies. The company emphasizes the potential of its genetically modified gamma-delta T cells which are engineered to be chemotherapy-resistant, thereby enabling their effective use in combination with standard-of-care treatments. Its strategic portfolio reflects a deliberate focus on creating therapies that provide robust antitumor activity with a favorable safety profile, which is crucial in clinical settings.
Market Position and Competitive Landscape
Operating within a competitive and dynamic segment of the biotechnology and oncology markets, In8Bio distinguishes itself by being one of the first companies to translate genetically modified gamma-delta T cell therapy into clinical studies. The company’s efforts to integrate advanced cell therapy with conventional cancer management protocols underscore its role as a pioneer in the immunotherapy space. Its scientific and clinical strategies are rooted in extensive research, aiming to expand treatment options for patients with unmet medical needs while setting a benchmark for future research in cell-based therapies.
Research and Development Focus
The core of In8Bio’s business model lies in its commitment to rigorous research and clinical validation. The company employs a systematic approach to clinical investigation, ensuring that its product candidates are evaluated through well-designed studies. This commitment to science and robust clinical trial methodologies not only enhances the credibility of its findings but also contributes to the broader scientific understanding of gamma-delta T cell functions in oncology. The integration of innovative technologies with traditional treatment regimens speaks to the company’s strategy of enhancing therapeutic durability and safety.
Operational Excellence and Strategic Vision
In8Bio is characterized by its deep commitment to scientific excellence and operational transparency. Its research pipeline is supported by meticulous clinical studies that investigate both short-term efficacy and long-term safety profiles of its cell therapies. By positioning its programs at the interface of immunology and oncology, the company provides a pertinent example of how novel biotechnology can offer alternative options for cancer patients. This blend of advanced immunotherapeutic strategies and rigorous clinical science reinforces In8Bio’s reputation as a credible and knowledgeable entity in the biopharmaceutical landscape.
Investor Insights and Frequently Asked Questions
Investors and industry researchers looking into In8Bio will find that the company’s emphasis on gamma-delta T cell therapies offers a unique intersection of cellular immunotherapy and targeted cancer treatments. The detailed clinical programs, alongside strategic R&D initiatives, provide ample context on the company’s approach to addressing unmet needs in oncology. By maintaining a balanced perspective on both the promise and challenges inherent in advanced cell therapies, In8Bio continues to contribute to the evolution of cancer treatment paradigms with ongoing scientific rigor and clinical evaluation.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced the successful results of its non-signaling gamma-delta CAR-T platform (nsCAR), which targets leukemic cells while preserving healthy B cells. Presented at the 6th CAR-TCR Summit Europe, the nsCAR platform exhibited a greater than 15x difference in cytotoxicity between leukemic cells and healthy B cells. This innovative approach promises to enhance CAR technology for previously 'undruggable' tumors, including acute myeloid leukemia (AML). IN8bio aims to expand its applications in solid tumors, with future clinical trials planned for this promising technology.
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced that CEO William Ho will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 1:30 pm ET. This presentation aims to highlight IN8bio's innovative gamma-delta T cell therapies for solid and liquid tumors. The event will be available live and as a replay on the company's website. IN8bio is conducting Phase 1 trials for its lead candidates, INB-200 and INB-100, and is set to launch a Phase 2 trial for INB-400 in glioblastoma, following IND clearance in late 2022. For further information, visit IN8bio's website.
IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will present at the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 12:00pm ET. The conference will showcase IN8bio’s innovative gamma-delta T cell therapies for solid and liquid tumors, emphasizing their unique ability to differentiate healthy from diseased tissues. Currently, IN8bio is conducting two Phase 1 clinical trials for its leading candidates: INB-200 targeting glioblastoma and INB-100 for leukemia patients. A Phase 2 trial, INB-400, is also set to begin post-IND clearance. For further details, visit IN8bio.com.
IN8bio, a clinical-stage biopharmaceutical company, reported promising initial data from its Phase 1 trial of INB-200 in newly diagnosed glioblastoma multiforme (GBM). All three patients in Cohort 2 exceeded the median progression-free survival of seven months, with responses ongoing beyond 1.5 years. The company aims to start a Phase 2 trial of INB-400 by Q3 2023 and anticipates submitting an IND for INB-410 in 2H 2023. No serious adverse events related to treatment have been reported, indicating a favorable safety profile.
IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical leader in gamma-delta T cell therapies, announced that CEO William Ho will present at the Biotech Showcase 2023 on January 9, 2023. The company will participate in a panel discussion on innovative gene and cell therapy approaches on January 10. This event will occur at the Hilton San Francisco Union Square, coinciding with the 41st Annual J.P. Morgan Healthcare Conference from January 9-11, 2023. IN8bio is currently advancing several clinical trials for its lead products targeting glioblastoma and leukemia.
IN8bio announced positive results from the Phase 1 trial of INB-100, a gamma-delta T cell therapy for hematological malignancies. Patients in the first cohort showed durable responses, remaining progression-free for over 2.5 years. Notably, 4 patients treated at the first dose level have maintained remission, with no dose-limiting toxicities reported. Enrollment for Cohort 2 has begun, with updates anticipated in Q2 2023. The results highlight INB-100's potential to improve cure rates in high-risk acute myeloid leukemia patients undergoing haploidentical stem cell transplantation.
IN8bio has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of INB-400, targeting newly diagnosed glioblastoma. The trial aims to assess the safety and efficacy of genetically modified DeltEx drug-resistant immunotherapy cells at various U.S. medical centers. This milestone marks IN8bio's first company-sponsored IND and sets the stage for further exploration of its DeltEx platform across solid tumor cancers. A conference call will be held on December 12 to discuss updated data from the ongoing Phase 1 trial of INB-100.
IN8bio, Inc. (Nasdaq: INAB) reported significant progress in its third quarter 2022 updates. The Phase 1 trial of INB-100 in leukemia patients showed durable morphologic complete responses with no dose-limiting toxicities. The company raised $9.8 million through an equity offering, boosting its cash position to $27.6 million. Additionally, IN8bio partnered with the Dunbar CAR T-Cell Program for INB-400 GMP production and expanded its R&D efforts, although it reported a net loss of $7.4 million for the quarter.
IN8bio, Inc. (Nasdaq: INAB) announced promising early results from its ongoing Phase 1 trial of INB-100, targeting high-risk acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplant. Notably, all three patients in Cohort 1 are alive and progression-free, with response durations exceeding 12 to 26.5 months. The safety profile remains manageable, with no dose-limiting toxicities observed. Updated data will be presented at the upcoming ASH Annual Meeting on December 11, 2022, highlighting the potential of INB-100 to impact AML treatment paradigms.
IN8bio, a clinical-stage biopharmaceutical company, has announced that CEO William Ho will present at two investor conferences in November 2022. He will participate in the BioFuture 2022 on November 8, presenting at 9:30 a.m. ET and again at 2:30 p.m. ET. Additionally, he will present at the Stifel 2022 Healthcare Conference on November 15 at 10:20 a.m. ET. The Stifel presentation will be available live and as a replay on the company's website. IN8bio is focused on developing gamma-delta T cell therapies for solid and liquid tumors.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
What is the primary focus of In8Bio, Inc.?
How does In8Bio approach cancer treatment differently?
Which types of cancers does In8Bio target?
What makes the company’s technology innovative?
How does In8Bio ensure the safety of its therapies?
In what stage of development is In8Bio’s therapy pipeline?
How does In8Bio differentiate itself from other biopharmaceutical companies?
What benefits do gamma-delta T cells offer in cancer treatment?
